Some anti-cancer therapies might inhibit the activity of ADAM17, which in theory would decrease the release of soluble ACE2 in the circulation or extracellular compartment and subsequently enhance the internalization of SARS-CoV-2 into the cells. The gene discussed is ADAM17; the disease is cancer.